Review Registration - Organization

This version of the registration was submitted prior to the Lobbying Transparency Act coming into force on May 4, 2020. Due to different information requirements at that time, the registration is presented in the following format.

Registration ID: 942431
Submitted by lobbyist on: April 12, 2019 10:28:52 AM
Accepted by Registrar on: April 12, 2019 10:57:13 AM

Designated Filer Information

Van Acker, Anna  
16750 TransCanada Highway  
Kirkland, QC, H9H 4M7
514-428-2638
Canada  

Organization Information

MERCK CANADA INC.  
For over a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola. For more information about our operations in Canada, visit www.merck.ca and connect with us on YouTube and Twitter @MerckCanada.
16750 TransCanada Highway  
Kirkland, QC, H9H 4M7
604-643-7996
Canada  

Relevant Affiliates


Type:

Business Name Mailing Address Contact Information
Merck & Co. 1959 Upper Water Street Suite 900
Halifax, NS
B3J 2X2
Canada
Phone: 604-643-7996

Government or Government Agency Funding


The organization does not receive any funding from a government or government agency.

Other Controlling or Directing Interests

The organization has no other controlling or directing interests.

Active Registration Period

April 12, 2019  
October 12, 2019  

Organization's In-House Lobbyists

 



Name: Barber, Caroline
 
April 12, 2019  
Inactivation Date: November 7, 2019

BC Public Office Background

This individual has not held any public office positions in BC.

Lobbying Activities

Health

Arranging meeting between an individual and a public office holder for purpose of lobbying

Awarding, amendment or termination of a contract, grant or financial benefit

Development, establishment, amendment or termination of any program, policy or decision

Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.

Target Contacts

Target Type Name Title or Constituency Date Added
Public Agency Health April 12, 2019
Public Agency Provincial Health Services Authority April 12, 2019

Name: Chan, Jennifer
 
April 12, 2019  
Inactivation Date: November 7, 2019

BC Public Office Background

This individual has not held any public office positions in BC.

Lobbying Activities

Health

Arranging meeting between an individual and a public office holder for purpose of lobbying

Awarding, amendment or termination of a contract, grant or financial benefit

Development, establishment, amendment or termination of any program, policy or decision

Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.

Target Contacts

Target Type Name Title or Constituency Date Added
Public Agency Health April 12, 2019

Name: Chen, Peter
 
April 12, 2019  
Inactivation Date: November 7, 2019

BC Public Office Background

This individual has not held any public office positions in BC.

Lobbying Activities

Health

Awarding, amendment or termination of a contract, grant or financial benefit

Development, establishment, amendment or termination of any program, policy or decision

Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.

Target Contacts

Target Type Name Title or Constituency Date Added
Public Agency Provincial Health Services Authority April 12, 2019

Name: Dagher, Jade
 
September 12, 2019  
Inactivation Date: November 7, 2019

BC Public Office Background

This individual has not held any public office positions in BC.

Lobbying Activities

Health

Arranging meeting between an individual and a public office holder for purpose of lobbying

Awarding, amendment or termination of a contract, grant or financial benefit

Development, establishment, amendment or termination of any program, policy or decision

Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.

Target Contacts

Target Type Name Title or Constituency Date Added
Public Agency Health September 12, 2019

Name: Foord, Leslie
 
April 12, 2019  
Inactivation Date: September 23, 2019

BC Public Office Background

This individual has not held any public office positions in BC.

Lobbying Activities

Mental Health and Addictions

Arranging meeting between an individual and a public office holder for purpose of lobbying

Awarding, amendment or termination of a contract, grant or financial benefit

Development, establishment, amendment or termination of any program, policy or decision

Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.

Target Contacts

Target Type Name Title or Constituency Date Added
Minister Dix, Adrian Minister of Health April 12, 2019
Minister Ralston, Bruce Minister of Jobs, Trade and Technology April 12, 2019
Staff of Minister Singh, Jasmyn Minister of Health April 12, 2019
MLA Barnett, Donna Cariboo-Chilcotin April 12, 2019
MLA Brar, Jagrup Surrey-Fleetwood April 12, 2019
MLA Cadieux, Stephanie Surrey South April 12, 2019
MLA Chen, Katrina Burnaby-Lougheed April 12, 2019
MLA Davies, Dan Peace River North April 12, 2019
MLA Dean, Mitzi Esquimalt-Metchosin April 12, 2019
MLA Furstenau, Sonia Cowichan Valley April 12, 2019
MLA Glumac, Rick Port Moody-Coquitlam April 12, 2019
MLA Hunt, Marvin Surrey-Cloverdale April 12, 2019
MLA Isaacs, Joan Coquitlam-Burke Mountain April 12, 2019
MLA Kahlon, Ravi Delta North April 12, 2019
MLA Larson, Linda Boundary-Similkameen April 12, 2019
MLA Lee, Michael Vancouver-Langara April 12, 2019
MLA Letnick, Norm Kelowna-Lake Country April 12, 2019
MLA Ma, Bowinn North Vancouver-Lonsdale April 12, 2019
MLA Paton, Ian Delta South April 12, 2019
MLA Redies, Tracy Surrey-White Rock April 12, 2019
MLA Robinson, Selina Coquitlam-Maillardville April 12, 2019
MLA Routledge, Janet Burnaby North April 12, 2019
MLA Simpson, Shane Vancouver-Hastings April 12, 2019
MLA Singh, Rachna Surrey-Green Timbers April 12, 2019
Public Agency Provincial Health Services Authority April 12, 2019

Name: Foord, Leslie
 
September 23, 2019  
Inactivation Date: November 7, 2019

BC Public Office Background

This individual has not held any public office positions in BC.

Lobbying Activities

Health

Arranging meeting between an individual and a public office holder for purpose of lobbying

Awarding, amendment or termination of a contract, grant or financial benefit

Development, establishment, amendment or termination of any program, policy or decision

Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.

Target Contacts

Target Type Name Title or Constituency Date Added
Minister Dix, Adrian Minister of Health September 23, 2019
Minister Ralston, Bruce Minister of Jobs, Trade and Technology September 23, 2019
Staff of Minister Singh, Jasmyn Minister of Health September 23, 2019
MLA Barnett, Donna Cariboo-Chilcotin September 23, 2019
MLA Brar, Jagrup Surrey-Fleetwood September 23, 2019
MLA Cadieux, Stephanie Surrey South September 23, 2019
MLA Chen, Katrina Burnaby-Lougheed September 23, 2019
MLA Davies, Dan Peace River North September 23, 2019
MLA Dean, Mitzi Esquimalt-Metchosin September 23, 2019
MLA Furstenau, Sonia Cowichan Valley September 23, 2019
MLA Glumac, Rick Port Moody-Coquitlam September 23, 2019
MLA Hunt, Marvin Surrey-Cloverdale September 23, 2019
MLA Isaacs, Joan Coquitlam-Burke Mountain September 23, 2019
MLA Kahlon, Ravi Delta North September 23, 2019
MLA Larson, Linda Boundary-Similkameen September 23, 2019
MLA Lee, Michael Vancouver-Langara September 23, 2019
MLA Letnick, Norm Kelowna-Lake Country September 23, 2019
MLA Ma, Bowinn North Vancouver-Lonsdale September 23, 2019
MLA Paton, Ian Delta South September 23, 2019
MLA Polak, Mary Langley September 23, 2019
MLA Redies, Tracy Surrey-White Rock September 23, 2019
MLA Robinson, Selina Coquitlam-Maillardville September 23, 2019
MLA Routledge, Janet Burnaby North September 23, 2019
MLA Simpson, Shane Vancouver-Hastings September 23, 2019
MLA Singh, Rachna Surrey-Green Timbers September 23, 2019
MLA Yap, John Richmond-Steveston September 23, 2019
Public Agency Provincial Health Services Authority September 23, 2019

Name: Gyuk, Cynthia
 
April 12, 2019  
Inactivation Date: September 23, 2019

BC Public Office Background

This individual has not held any public office positions in BC.

Lobbying Activities

Health

Awarding, amendment or termination of a contract, grant or financial benefit

Development, establishment, amendment or termination of any program, policy or decision

Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.

Target Contacts

Target Type Name Title or Constituency Date Added
Public Agency Provincial Health Services Authority April 12, 2019

Name: Jarema, Chad
 
April 12, 2019  
Inactivation Date: November 7, 2019

BC Public Office Background

This individual has not held any public office positions in BC.

Lobbying Activities

Health

Arranging meeting between an individual and a public office holder for purpose of lobbying

Awarding, amendment or termination of a contract, grant or financial benefit

Development, establishment, amendment or termination of any program, policy or decision

Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.

Target Contacts

Target Type Name Title or Constituency Date Added
Public Agency Health April 12, 2019

Name: Kam, Lonnie
 
April 12, 2019  
Inactivation Date: November 7, 2019

BC Public Office Background

This individual has not held any public office positions in BC.

Lobbying Activities

Health

Arranging meeting between an individual and a public office holder for purpose of lobbying

Awarding, amendment or termination of a contract, grant or financial benefit

Development, establishment, amendment or termination of any program, policy or decision

Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.

Target Contacts

Target Type Name Title or Constituency Date Added
Public Agency Health April 12, 2019

Name: Lafontaine, Manon
 
April 12, 2019  
Inactivation Date: September 12, 2019

BC Public Office Background

This individual has not held any public office positions in BC.

Lobbying Activities

Health

Arranging meeting between an individual and a public office holder for purpose of lobbying

Awarding, amendment or termination of a contract, grant or financial benefit

Development, establishment, amendment or termination of any program, policy or decision

Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.

Target Contacts

Target Type Name Title or Constituency Date Added
Public Agency Health April 12, 2019

Name: Lutterodt, Lant
 
April 12, 2019  
Inactivation Date: November 7, 2019

BC Public Office Background

This individual has not held any public office positions in BC.

Lobbying Activities

Health

Awarding, amendment or termination of a contract, grant or financial benefit

Development, establishment, amendment or termination of any program, policy or decision

Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.

Target Contacts

Target Type Name Title or Constituency Date Added
Public Agency Provincial Health Services Authority April 12, 2019

Name: McIntyre, Jocelyn
 
April 12, 2019  
Inactivation Date: September 23, 2019

BC Public Office Background

This individual has not held any public office positions in BC.

Lobbying Activities

Health

Awarding, amendment or termination of a contract, grant or financial benefit

Development, establishment, amendment or termination of any program, policy or decision

Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.

Target Contacts

Target Type Name Title or Constituency Date Added
Public Agency Provincial Health Services Authority April 12, 2019

Name: Miyai, Wes
 
April 12, 2019  
Inactivation Date: November 7, 2019

BC Public Office Background

This individual has not held any public office positions in BC.

Lobbying Activities

Health

Arranging meeting between an individual and a public office holder for purpose of lobbying

Awarding, amendment or termination of a contract, grant or financial benefit

Development, establishment, amendment or termination of any program, policy or decision

Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.

Target Contacts

Target Type Name Title or Constituency Date Added
Public Agency Health April 12, 2019
Public Agency Provincial Health Services Authority April 12, 2019

Name: Nicholls, Christopher
 
April 12, 2019  
Inactivation Date: November 7, 2019

BC Public Office Background

This individual has not held any public office positions in BC.

Lobbying Activities

Health

Awarding, amendment or termination of a contract, grant or financial benefit

Development, establishment, amendment or termination of any program, policy or decision

Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.

Target Contacts

Target Type Name Title or Constituency Date Added
Public Agency Provincial Health Services Authority April 12, 2019

Name: Smith, Kirby
 
April 12, 2019  
Inactivation Date: November 7, 2019

BC Public Office Background

This individual has not held any public office positions in BC.

Lobbying Activities

Health

Arranging meeting between an individual and a public office holder for purpose of lobbying

Awarding, amendment or termination of a contract, grant or financial benefit

Development, establishment, amendment or termination of any program, policy or decision

Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.

Target Contacts

Target Type Name Title or Constituency Date Added
Minister Dix, Adrian Minister of Health April 12, 2019
Minister Ralston, Bruce Minister of Jobs, Trade and Technology April 12, 2019
Staff of Minister Singh, Jasmyn Minister of Health April 12, 2019
Public Agency Health April 12, 2019
Public Agency The University of British Columbia April 12, 2019

Name: Swift, Lee
 
April 12, 2019  
Inactivation Date: September 23, 2019

BC Public Office Background

This individual has not held any public office positions in BC.

Lobbying Activities

Mental Health and Addictions

Arranging meeting between an individual and a public office holder for purpose of lobbying

Awarding, amendment or termination of a contract, grant or financial benefit

Development, establishment, amendment or termination of any program, policy or decision

Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.

Target Contacts

Target Type Name Title or Constituency Date Added
Minister Dix, Adrian Minister of Health April 12, 2019
Staff of Minister Oreck, Mira Premier April 12, 2019
Minister Ralston, Bruce Minister of Jobs, Trade and Technology April 12, 2019
Staff of Minister Singh, Jasmyn Minister of Health April 12, 2019
MLA Brar, Jagrup Surrey-Fleetwood April 12, 2019
MLA Chen, Katrina Burnaby-Lougheed April 12, 2019
MLA Davies, Dan Peace River North April 12, 2019
MLA Furstenau, Sonia Cowichan Valley April 12, 2019
MLA Glumac, Rick Port Moody-Coquitlam April 12, 2019
MLA Kahlon, Ravi Delta North April 12, 2019
MLA Larson, Linda Boundary-Similkameen April 12, 2019
MLA Lee, Michael Vancouver-Langara April 12, 2019
MLA Letnick, Norm Kelowna-Lake Country April 12, 2019
MLA Ma, Bowinn North Vancouver-Lonsdale April 12, 2019
MLA Paton, Ian Delta South April 12, 2019
MLA Routledge, Janet Burnaby North April 12, 2019
MLA Singh, Rachna Surrey-Green Timbers April 12, 2019
Public Agency Health April 12, 2019

Name: Swift, Lee
 
September 23, 2019  
Inactivation Date: November 7, 2019

BC Public Office Background

This individual has not held any public office positions in BC.

Lobbying Activities

Health

Arranging meeting between an individual and a public office holder for purpose of lobbying

Awarding, amendment or termination of a contract, grant or financial benefit

Development, establishment, amendment or termination of any program, policy or decision

Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.

Target Contacts

Target Type Name Title or Constituency Date Added
Minister Bains, Harry Minister of Labour September 23, 2019
Minister Darcy, Judy Minister of Mental Health and Addictions September 23, 2019
Minister Dix, Adrian Minister of Health September 23, 2019
Staff of Minister Orek, Mira Premier September 23, 2019
Minister Ralston, Bruce Minister of Jobs, Trade and Technology September 23, 2019
Staff of Minister Singh, Jasmyn Minister of Health September 23, 2019
MLA Brar, Jagrup Surrey-Fleetwood September 23, 2019
MLA Cadieux, Stephanie Surrey South September 23, 2019
MLA Chen, Katrina Burnaby-Lougheed September 23, 2019
MLA Davies, Dan Peace River North September 23, 2019
MLA Furstenau, Sonia Cowichan Valley September 23, 2019
MLA Glumac, Rick Port Moody-Coquitlam September 23, 2019
MLA Kahlon, Ravi Delta North September 23, 2019
MLA Larson, Linda Boundary-Similkameen September 23, 2019
MLA Lee, Michael Vancouver-Langara September 23, 2019
MLA Letnick, Norm Kelowna-Lake Country September 23, 2019
MLA Ma, Bowinn North Vancouver-Lonsdale September 23, 2019
MLA Paton, Ian Delta South September 23, 2019
MLA Polak, Mary Langley September 23, 2019
MLA Routledge, Janet Burnaby North September 23, 2019
MLA Singh, Rachna Surrey-Green Timbers September 23, 2019
MLA Yap, John Richmond-Steveston September 23, 2019
Public Agency Health September 23, 2019

Name: VanAcker, Anna
 
April 12, 2019  
Inactivation Date: November 7, 2019

BC Public Office Background

This individual has not held any public office positions in BC.

Lobbying Activities

Health

Arranging meeting between an individual and a public office holder for purpose of lobbying

Awarding, amendment or termination of a contract, grant or financial benefit

Development, establishment, amendment or termination of any program, policy or decision

Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.

Target Contacts

Target Type Name Title or Constituency Date Added
Public Agency Health April 12, 2019

Name: van Dijk, Leo
 
April 12, 2019  
Inactivation Date: November 7, 2019

BC Public Office Background

This individual has not held any public office positions in BC.

Lobbying Activities

Health

Arranging meeting between an individual and a public office holder for purpose of lobbying

Awarding, amendment or termination of a contract, grant or financial benefit

Development, establishment, amendment or termination of any program, policy or decision

Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.

Target Contacts

Target Type Name Title or Constituency Date Added
Public Agency Health April 12, 2019